Kratom withdrawal onset: 12–24 hours. Peak: days 2–3 (muscle aches, insomnia, restless legs, anxiety). Acute physical symptoms largely resolve days 5–7. Subacute mood/energy dysregulation: weeks 2–8. Most heavy users feel genuinely better by week 4 than during active kratom use.
Kratom's active alkaloids, mitragynine and 7-hydroxymitragynine, bind to mu-opioid receptors. This makes kratom withdrawal similar to opioid withdrawal in character, though typically milder in severity for most users.
Restlessness, mild anxiety, and early muscle discomfort appear as kratom's alkaloids begin clearing. Yawning and watery eyes, classic opioid withdrawal early signs, may appear. Emotional irritability increases.
What helps: Hydrate. Electrolytes. This is manageable. It peaks, then improves.
Symptoms peak: muscle aches and cramps, restless leg syndrome, severe insomnia (inability to stay still enough to sleep), hot and cold sweats, nausea, and possibly vomiting or diarrhea. Anxiety and dysphoria are intense. Cravings are strong.
What helps: Clonidine or hydroxyzine (physician-prescribed for symptom relief), loperamide for diarrhea, heating pad for muscle aches, dark quiet room, support person if possible.
Muscle aches and GI symptoms start to improve. Restless legs may persist. Insomnia continues, the hardest symptom to resolve quickly. Anxiety remains elevated. Mental symptoms more prominent as physical symptoms recede.
What helps: Light walks outside (helps restless legs and mood), protein-rich meals, melatonin for sleep.
Most physical symptoms have largely resolved. Sleep begins to return, though may remain disrupted for weeks. Appetite returning. Mood still low, anhedonia and anxiety persist into the subacute phase.
For most people, the phrase "I made it through the worst" is accurate at day 7.
Physical symptoms largely gone. Lingering: low mood, anxiety (often worse in mornings), low energy, occasional insomnia. Cravings shift from physical to psychological, triggered by stress, boredom, or habit cues.
Key insight: many people report feeling better at week 4 than they did during kratom use, because the cyclical anxiety and energy crashes from dosing are gone.
For most kratom users, baseline mood and energy are restored by weeks 4–8. Sleep is normal. Anxiety manageable. Appetite and GI function normal (opioid-induced constipation fully resolved). The period of feeling "genuinely okay without kratom" has arrived for the majority.
Heavy, long-term users may take slightly longer, up to 3 months for full stabilization.
Full opioid withdrawal (heroin, oxycodone, fentanyl) typically involves more intense acute symptoms and a longer PAWS window. Kratom acts at the mu-opioid receptor, but mitragynine and 7-hydroxymitragynine are partial agonists with lower intrinsic activity than full opioids like morphine or fentanyl.
This partial agonism means the receptor downregulation caused by kratom is less severe, resulting in a shorter and typically less intense withdrawal compared to full-agonist opioids. However, for very heavy, long-term kratom users (high daily doses), the difference may be smaller.
Weiss et al. (2022, PMID 34723855): buprenorphine was superior to symptomatic management for kratom withdrawal, evidence that the opioid mechanism is real and clinically addressable.
Evidence-based approaches: (1) Off-label buprenorphine under physician supervision. Most effective for moderate-to-severe withdrawal. (2) Clonidine, reduces sympathetic nervous system hyperactivity (sweating, anxiety, heart rate). (3) Hydroxyzine or diphenhydramine, for sleep and anxiety. (4) NSAIDs and heating pad, for muscle aches. (5) Loperamide, for GI symptoms. (6) Electrolytes and hydration, crucial for GI losses. Exercise and support network are helpful throughout.
Most people report kratom withdrawal as similar in character to opioid withdrawal but typically less severe, especially for those who have experienced both. The exception: some people who used high-dose kratom daily for years describe very intense withdrawal comparable to short-acting opioid withdrawal. Duration is generally shorter than opioid PAWS. Character of symptoms (muscle aches, insomnia, GI) is nearly identical.
Kratom PAWS is real but shorter than opioid PAWS. Typical duration: 2–8 weeks post-acute. Symptoms: low motivation, anxiety (especially morning), low energy, occasional insomnia, and low-grade cravings triggered by stress or habit cues. The good news: most heavy users find that by week 4, their mood and energy are actually better than during active kratom use, because the dosing cycle's anxiety-and-crash pattern is gone.
OTC options: loperamide (Imodium) for GI symptoms, don't exceed recommended doses, hydroxyzine or diphenhydramine for anxiety and sleep, NSAIDs for muscle pain, hot baths for aches. Prescription: clonidine significantly helps autonomic symptoms, buprenorphine can shorten and reduce severity of withdrawal for severe cases. If withdrawal is severe, call a doctor rather than white-knuckling it.
Generally milder than withdrawal from prescription opioids or heroin, similar duration (5–7 days acute) but typically lower intensity. The exception: heavy users taking dozens of grams per day of high-mitragynine kratom may experience severe withdrawal that closely resembles opioid withdrawal. The degree of difficulty depends heavily on dose, duration of use, and individual physiology.
Acute cravings are most intense during days 1–7 and diminish significantly through weeks 2–4. Psychological cravings, triggered by stress, boredom, or pain, can persist for weeks to months. Many people used kratom to manage underlying pain or anxiety, so addressing the root cause is critical. Most people report manageable cravings by weeks 4–8.
See how much money you've saved by quitting:
Calculate Your Savings → · How long have you been sober? →The first 24 hours after stopping kratom mark the onset of withdrawal, which begins earlier than many people expect due to kratom's relatively short half-life. Kratom's half-life: mitragynine, kratom's primary active alkaloid, has a half-life of approximately 9-10 hours, this means withdrawal can begin within 12-16 hours of the last dose for regular users, and people who use kratom multiple times daily may notice early withdrawal symptoms within 8-12 hours. Early symptoms (hours 8-16): initial restlessness and anxiety, subtle muscle aches beginning, yawning, a classic opioid withdrawal sign, and runny nose. Peak early symptoms (hours 16-24): the symptoms of kratom withdrawal mirror opioid withdrawal because mitragynine acts on opioid receptors, muscle aches and joint pain becoming prominent, nausea developing, insomnia with restlessness making sleep difficult, anxiety increasing, and irritability. Why kratom withdrawal is like opioid withdrawal: mitragynine and 7-hydroxymitragynine, kratom's alkaloids, are partial agonists at the mu-opioid receptor, this is the same receptor targeted by morphine, heroin, and prescription opioids, the brain develops opioid-like dependence, and withdrawal produces opioid-like symptoms. Variation by use pattern: people using kratom multiple times daily for extended periods will experience more prominent first-24-hour symptoms, people using lower doses or less frequently may have milder onset, and the dose and duration of use are the primary determinants of withdrawal severity.
Kratom withdrawal follows a timeline similar to opioid withdrawal, though typically less severe for most users, with distinct phases that evolve over days to weeks. Days 1-3 (acute phase): symptoms begin within 12-24 hours of last dose, peak intensity typically occurs at days 2-3, primary symptoms include muscle aches, insomnia, nausea, sweating, anxiety, and irritability, physical symptoms are most prominent during this phase. Days 3-7 (ongoing acute withdrawal): physical symptoms begin gradually improving, psychological symptoms including anxiety and depression become more prominent as physical symptoms recede, insomnia often persists, and cravings are intense. Days 7-14 (sub-acute withdrawal): physical symptoms largely resolve for most users, mood disturbances including depression and anxiety continue, fatigue and low energy are prominent, and sleep gradually improves. Weeks 2-4 (recovery): most physical symptoms have resolved, mood remains unstable and may dip into depression, motivation and energy gradually return, and cravings become more episodic. Months 1-3 (PAWS): for heavy, long-term kratom users, intermittent mood disturbances, fatigue that can be significant, and cravings triggered by stress or cues. Factors affecting timeline: dose and duration of use are the primary variables, people using high doses (above 15-20 grams daily) for years will have more extended timelines, those using lower doses for shorter periods typically resolve within 1-2 weeks, and individual variation in opioid receptor sensitivity affects recovery pace.
Kratom withdrawal is generally not life-threatening in the way that alcohol or benzodiazepine withdrawal can be, but it is physically and psychologically significant and can be more challenging than many people anticipate. Physical safety profile: kratom withdrawal does not typically cause seizures or life-threatening physiological events in the way alcohol or benzo withdrawal can, cardiovascular effects are generally mild in people without pre-existing conditions, and from a purely physical safety standpoint, most people can manage kratom withdrawal without medical intervention. The psychiatric risks: the depression and anxiety of kratom withdrawal can be severe, suicidal ideation, while not the norm, has been reported during kratom withdrawal, and people with a history of depression or other mental health conditions are at higher risk for psychiatric complications. The severity underestimation: kratom is often marketed as a natural product with minimal dependence risk, many users are surprised by the severity of withdrawal, particularly the psychological component, and the expectation that withdrawal will be easy contributes to inadequate preparation. High-dose, long-term user considerations: people using very high doses (above 20 grams daily) for years may experience more severe withdrawal, cardiac effects are more significant at higher doses, and medical supervision is appropriate for this population. Co-occurring substance use: kratom is sometimes used to self-treat opioid use disorder, people with concurrent opioid use will experience combined withdrawal, and distinguishing kratom withdrawal from opioid withdrawal requires knowing the full substance use picture. When to seek medical help: severe nausea and vomiting preventing adequate hydration, significant cardiovascular symptoms (chest pain, severe palpitations), severe psychological symptoms including suicidal ideation, and unsuccessful previous quit attempts all suggest medical support is appropriate.
Kratom withdrawal produces a distinctive set of symptoms that parallel opioid withdrawal, reflecting kratom's mechanism of action at opioid receptors, with some unique features reflecting kratom's specific alkaloid profile. Musculoskeletal symptoms: muscle aches are among the most consistently reported and prominent symptoms, joint pain is common, restless legs syndrome (an irresistible urge to move the legs, particularly at night), and generalized physical discomfort and malaise. Gastrointestinal symptoms: nausea, ranging from mild to severe, vomiting in significant withdrawal, diarrhea, particularly in the first days, abdominal cramping, and loss of appetite. Autonomic nervous system symptoms: sweating, often profuse and unpredictable, hot and cold flashes, runny nose and watery eyes (similar to opioid withdrawal), goosebumps (piloerection), and yawning. Sleep disturbance: insomnia is nearly universal and often described as the most difficult symptom, the combination of physical discomfort (restless legs, aches) and psychological agitation makes sleep difficult, vivid dreams when sleep does occur, and the fatigue from sleep deprivation compounds all other symptoms. Psychological symptoms: anxiety, often severe, irritability and emotional reactivity, depression that typically emerges as physical symptoms recede, anhedonia - reduced ability to experience pleasure, and cravings that are often intense and persistent. Cognitive effects: difficulty concentrating, mental fatigue, and the 'foggy' thinking that reflects opioid receptor withdrawal affecting cognition. The intensity spectrum: people using low doses (2-5 grams) for short periods may experience primarily mild versions of the above, heavy, long-term users (15+ grams daily for years) will experience more severe versions of all the above symptoms.
Managing kratom withdrawal effectively involves addressing the specific symptom clusters that are most prominent, with both supportive care and targeted interventions. For muscle aches and physical discomfort: hot baths or showers provide significant temporary relief, heating pads for localized aches, over-the-counter NSAIDs (ibuprofen, naproxen) reduce inflammation-related pain, and gentle stretching when comfortable. For gastrointestinal symptoms: for nausea, anti-nausea medications (promethazine, ondansetron by prescription, dimenhydrinate over the counter), eating small amounts of bland food when nausea permits, for diarrhea, loperamide (Imodium) reduces symptoms, and staying hydrated is critical when nausea and diarrhea are depleting fluids. For insomnia and restlessness: magnesium glycinate helps with muscle tension and sleep, melatonin (1-5mg) supports sleep initiation, diphenhydramine (Benadryl) or doxylamine for short-term sleep support, and dark, cool sleeping environment. For anxiety: deep breathing exercises and grounding techniques, hydroxyzine (by prescription) provides non-addictive anxiety relief, avoiding caffeine which worsens anxiety during withdrawal, and social support. Medical options for more severe withdrawal: low-dose clonidine (by prescription) significantly reduces autonomic symptoms including sweating, hot flashes, and anxiety, and in severe cases, a short course of buprenorphine can be used to ease withdrawal before tapering. Tapering versus abrupt cessation: many people find tapering kratom doses (reducing by 10-20% weekly) more manageable than abrupt cessation, switching to a lower-alkaloid form of kratom for tapering, and having a clear tapering schedule increases success rates.
Insomnia is consistently reported as one of the most difficult aspects of kratom withdrawal, and understanding its timeline and management helps people navigate this challenging symptom. Why kratom withdrawal causes insomnia: kratom's opioid receptor activity affects sleep architecture, opioid receptors are involved in sleep regulation, withdrawal hyperexcitability (similar to opioid withdrawal) makes relaxation and sleep onset difficult, restless legs syndrome, common in kratom withdrawal, specifically interferes with falling asleep, and the anxiety and physical discomfort of withdrawal compound the insomnia. The insomnia timeline: insomnia typically begins with the first withdrawal symptoms (day 1), is most severe during days 2-5 of acute withdrawal, begins improving as acute physical symptoms resolve (days 5-10), and most people see significant sleep improvement within 2-3 weeks. Factors that prolong insomnia: higher doses and longer duration of kratom use, pre-existing sleep disorders, co-occurring anxiety or depression, and poor sleep hygiene during withdrawal. Managing withdrawal insomnia: sleep hygiene fundamentals (consistent schedule, dark cool room, no screens), magnesium glycinate (400mg before bed) supports sleep and reduces restless legs, short-term antihistamines (diphenhydramine, doxylamine) for the first week, and melatonin (1-5mg 30 minutes before bed). When insomnia persists: insomnia beyond 2-3 weeks of abstinence may reflect PAWS or an underlying sleep disorder, medical evaluation is appropriate at this point, and treating underlying anxiety or depression often resolves persistent insomnia.
Depression is a common and clinically important consequence of kratom cessation, particularly for people who have been using kratom heavily for extended periods. Why quitting kratom causes depression: kratom's opioid receptor activity stimulates dopamine release in reward circuits, similar to other opioids, chronic stimulation leads to downregulation of dopamine receptors and reduced endogenous opioid activity, when kratom is removed, dopamine signaling falls below baseline, and depression is the clinical manifestation of this opioid/dopamine deficiency state. The depression timeline: depressive symptoms typically emerge as acute physical withdrawal symptoms begin to improve (days 3-7), depression is often most pronounced in weeks 1-4 of abstinence, gradual improvement occurs over weeks 4-12 as opioid receptors and dopamine function recover, and for heavy long-term users, depressive symptoms may persist at milder levels for months. The mood disorder complication: many people who develop heavy kratom use were initially self-medicating depression or anxiety, these underlying conditions can re-emerge or worsen during withdrawal, distinguishing withdrawal-induced depression from an underlying mood disorder requires clinical assessment after an adequate abstinence period. Anhedonia: the reduced ability to experience pleasure from normally rewarding activities is particularly prominent in the first weeks of kratom abstinence, this reflects the reduced opioid receptor activity that modulates pleasure, and most people find anhedonia substantially improves within 4-8 weeks. When to seek help for withdrawal depression: severe depression lasting more than 2-4 weeks, any suicidal thoughts, inability to function in daily activities, and when depression is preventing engagement with the recovery process all warrant professional support.
The question of using kratom to quit opioids is complicated, with genuine evidence of short-term opioid withdrawal relief alongside significant concerns about trading one dependence for another. Why people use kratom for opioid withdrawal: mitragynine and 7-hydroxymitragynine act at mu-opioid receptors, the same receptors that heroin, oxycodone, and fentanyl activate, this means kratom can relieve opioid withdrawal symptoms, and many people report successfully using kratom to get off opioids. The evidence: anecdotal and survey-based evidence consistently shows people reporting kratom as helpful for opioid cessation, controlled clinical studies are limited, and kratom's legal status has complicated research. The substitution concern: using kratom to stop opioids effectively substitutes one opioid-like substance for another, kratom dependence develops with regular use, and some people find themselves dependent on kratom after using it to stop opioids. How it plays out in practice: some people successfully taper and stop kratom after using it to bridge off opioids, others find themselves in a similar position to where they started, dependent on kratom, and the outcome seems to depend significantly on the person's intent and execution of a tapering plan. Comparing kratom to medication-assisted treatment: buprenorphine and methadone are FDA-approved medications with substantial evidence bases for opioid use disorder treatment, they carry their own dependence profiles but are medically supervised and dosed consistently, and for people with significant opioid use disorder, FDA-approved MAT is generally preferable to uncontrolled kratom use. The harm reduction context: for people who cannot or will not access MAT, kratom may represent a harm reduction option, transitioning from fentanyl or heroin to kratom likely reduces overdose risk, and this harm reduction consideration is distinct from endorsing kratom as equivalent to evidence-based treatment.
Kratom is sold in multiple strains and vein colors, and while the marketing around these distinctions is extensive, the relevance to withdrawal is more limited than often suggested. The strain marketing landscape: kratom is marketed in dozens of named strains (Maeng Da, Borneo, Bali, Thai, etc.) and three vein colors (red, green, white), marketers attribute different effects to each, and the evidence base for these distinctions is largely anecdotal. What the alkaloid variation actually means: different kratom preparations do have varying ratios of mitragynine, 7-hydroxymitragynine, and other alkaloids, 7-hydroxymitragynine is more potent at opioid receptors and more concerning from a dependence standpoint, and red vein kratom preparations generally have higher 7-hydroxymitragynine content. Relevance to withdrawal severity: people using high-7-hydroxymitragynine products (typically red vein, certain extracts, enhanced products) likely develop more significant opioid receptor dependence, withdrawal from these products may be more pronounced, and switching to lower-potency products as part of a taper can make tapering more manageable. Kratom extracts and enhanced products: these products concentrate kratom alkaloids to much higher potency than raw leaf, users of kratom extracts are at significantly higher risk for severe dependence and withdrawal, and this population is increasingly represented in kratom withdrawal discussions because of the potency increase in the market. The practical takeaway: strain names provide limited reliable guidance about withdrawal potential, dose and duration of use are more important predictors of withdrawal severity than strain, and people using extracts or enhanced products should expect more significant withdrawal than people using equivalent doses of raw leaf powder.
Post-Acute Withdrawal Syndrome (PAWS) from kratom is a less extensively studied but clinically recognized phenomenon where withdrawal-like symptoms persist beyond the acute withdrawal phase, particularly in heavy, long-term users. What kratom PAWS feels like: persistent low-grade depression and anxiety, fatigue and reduced energy, anhedonia - reduced ability to enjoy normally pleasurable activities, cravings that emerge episodically in response to stress or cues, and cognitive difficulties including concentration and memory. Why kratom PAWS occurs: opioid receptor normalization after chronic kratom use takes months, the endogenous opioid system (which regulates mood, pain, and reward) adapts to consistent exogenous stimulation, and when that stimulation is removed, the endogenous system functions below its natural baseline for an extended period during recovery. The timeline: acute withdrawal typically resolves within 1-2 weeks for most kratom users, PAWS symptoms, if they occur, typically begin emerging as acute symptoms resolve, most prominent in months 1-3, progressively improving through months 3-12, and largely resolved by 12 months for the majority of users. Variation by use history: people using low to moderate doses for less than a year are unlikely to experience significant PAWS, heavy, long-term users (high doses for years) are most at risk, and people who used potent kratom extracts may have PAWS more similar to pharmaceutical opioid PAWS. Managing kratom PAWS: aerobic exercise is the most evidence-supported natural intervention for opioid receptor recovery, consistent sleep schedule, nutrition and hydration, avoiding alcohol and other substances, ongoing recovery support, and treating co-occurring anxiety or depression with professional help if symptoms are persistent and significant.
Tapering kratom - gradually reducing dose over time rather than stopping abruptly - is generally a more manageable approach than cold turkey cessation, particularly for people who have been using significant doses for extended periods. Why tapering works: kratom's opioid receptor mechanism means that gradual reduction allows the opioid receptors to gradually upregulate toward normal levels, this produces milder withdrawal than abrupt cessation, and the physiological adjustment is spread over weeks to months rather than days. General tapering principles: reduce dose by approximately 10-20% per week, measure doses consistently (a scale is more reliable than volume measures), hold at a reduced dose when withdrawal symptoms are significant before further reduction, and avoid increasing the dose when cravings are high (normal progress includes cravings). Practical approaches: if using kratom powder, reduce the amount per dose first, then reduce the frequency of dosing, switching from multiple daily doses to fewer doses reduces the frequency of opioid receptor stimulation, and having a clear schedule written down helps avoid dose creep. Dealing with the lower end of the taper: the last portion of a taper (reducing from a low dose to zero) is often the most psychologically difficult even if not the most physically intense, having a definitive stopping point and date can be helpful, and some people find it easier to make the final jump from a very low dose rather than extending the taper indefinitely. Tapering aids: keeping a log of dose and timing helps maintain taper progress, reducing other stressors during the taper period, and building in accountability (a support person who knows the plan) supports adherence. When tapering alone is insufficient: if unable to taper below a certain dose due to intolerable withdrawal, if multiple taper attempts have failed, and if mental health symptoms are severe during tapering, medical support should be sought.
Several supplements have plausible mechanisms or anecdotal support for easing kratom withdrawal symptoms, though none replaces the core management approaches of tapering and supportive care. Magnesium glycinate: one of the most consistently recommended supplements, reduces muscle tension and cramping, supports sleep, and modulates NMDA receptors that become hyperactive during opioid-like withdrawal, 400-800mg before bed is typical. Black seed oil (Nigella sativa): widely reported in kratom communities as helpful for withdrawal, has some evidence for opioid receptor modulation, reduces anxiety and improves sleep in some users, and typical dose is 1-2 teaspoons twice daily. Valerian root: mild anxiolytic and sleep-supporting properties, may reduce the anxiety component of withdrawal, non-addictive at recommended doses, and can be combined with melatonin for sleep support. L-tyrosine: a dopamine precursor, some rationale for supporting dopamine levels depleted by opioid receptor-mediated dopamine dysregulation, typically taken in the morning to support daytime energy. Vitamin C: high-dose vitamin C has been used in some opioid detox protocols, antioxidant properties may support neurological recovery, and bowel tolerance dosing (spreading doses through the day up to bowel tolerance) is the typical approach in these protocols. B vitamins: support overall neurological function and energy metabolism, B vitamin deficiency worsens mood and cognitive function, and a complete B complex is a reasonable baseline supplement during withdrawal. What to avoid: supplements that are themselves psychoactive or carry dependence risk, any supplement not discussed with a physician in the context of other medications, and relying on supplements alone rather than addressing the core withdrawal process.
Forge marks your milestones and shows you which withdrawal phase you're in, day 2, week 4, and beyond.
Download Forge Free →Also from Forge
Forge Desktop blocks porn and gambling sites on your computer, and tells one person you choose if you turn the blocker off. $7/month, separate from the app.
It won't help with what this article is about. It blocks websites. It can't block a shop, a bar, or a dealer. Mentioned here only because people ask, and because it's the same account.
Look at Forge DesktopFor what you're reading about here, the Forge iPhone app is the right tool, streak tracking, an AI coach, and an SOS mode for when a craving peaks.
Forge Desktop is a separate product from the Forge iPhone app, with its own subscription. Paying for one doesn't include the other. If you already have Forge Pro on your phone, that stays exactly as it is.